Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность новой формы флупиртина (Катадолона Форте) в лечении острой боли в спине
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Smith TW, Aberger EW, Follick MJ, Ahern DK. Cognitive distortion and psychological distress in chronic lowback pain. J Consult Clin Psychol 1986; 54: 573–5.
2. Голубев В.Л. Боль – междисциплинарная проблема. РМЖ. 2008; 16 (Спец. вып.): 3–7.
3. Данилов А.Б., Коржавина В.Б. Современные методы терапии боли в спине. РМЖ.
4. Wörz R et al. Flupirtine in comparison with ehlomiezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (3536): 500–4.
5. Chou R, Qaseem A, Snow V et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Clinical Guidelines 2007.
6. Muller-Schwefe G, Uberall M. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW. Fortschr Med 2008; 149 (Suppl. 4): 153–61.
7. Bandura A, O’Leary A, Taylor СВ et al. Perceived self-efficacy and pain control: Opioid and nonopioid mechanisms. Personal and Social Psychology 1987; S3: 563–71.
8. Engel J. Flupirtine – a new central acting analgesic with unique chemical structure. Postgrad Med 1987; 63 (Suppl. 3): 15–7.
9. Hlavica P, Niebch G. Pharmacokinetics and biotransforma tion of the analgesic flupirtine in humans. Arzneimittelforschung 1985; 35 (1): 67–74.
10. Osborne NN, Cazevieille C, Wood J. Flupirtine, a Nonopioid Centrally Acting Analgesic, Acts as an NMDA Antagonist. Gen Pharmacol 1998; 30 (3): 255–63.
11. Michael A. Uberall et al. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1–18.
12. Болевые синдромы в неврологической практике. Под ред. чл.-кор. РАМН А.М.Вейна. М.: МЕДпресс-информ, 2001.
13. Кукушкин М.Л., Хитров Н.К. Общая патология боли.
М.: Медицина, 2004.
14. Darius H, Shror K. The action of Flupirtine on prostaglandine formation and platekets agregation in vitro. Arzneimittelforschung 1985; 35: 55–9.
15. Knost В, Flor H, Braun C, Birbaumer N. Cerebral processing of words and the development of chronic pain. Psychophysiology 1997; 34: 474–81.
16. Perovic S, Schleger C, Pergande G et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by NMDA and gpl20. Eur J Pharmacol Mol Pharmacol Sect 1994; 288: 27–33.
17. Schmidt C, Raspe H, Pfingsten M et al. Back pain in the German adult population. Spine 2007; 37 (18): 2005–11.
18. Bebenburg W von, Thiel K, Engel J, Sheldrick WS. Synthese und Molekulstruktur des konstitutionell neuartigen analgetikum Flupirtin. Chem Z 1981; 105: 77–81.
19. Szelenyi I, Nickel B, Borbe HO, Brune H. Mode of antinociceptive action on flupirtine in the rats. Br J Pharmacol 1989; 97: 835–42.
20. Von Korff M, Saunders K. The course of back pain in primary care. Spine. 1996; 21: 2833–7; discussion 2838–9 [PMID: 9112707].
21. Weiser T, Szelenyi I, Nickel B, Weinrich M. In vitro and in vivo findings about the muscle relaxing properties of flupirine. Naunyn-Schmiedeberg’s Arch Pharmacol 1992; 246 (Suppl. 1): R22.
22. Wörz R, Lobisch M, Schwittmann B et al. Effectiveness of flupirtine in chronic tension headache. Results of a double-blind study versus placebo. Fortschr Med 1995; 113 (32): 463–8.
2. Голубев В.Л. Боль – междисциплинарная проблема. РМЖ. 2008; 16 (Спец. вып.): 3–7.
3. Данилов А.Б., Коржавина В.Б. Современные методы терапии боли в спине. РМЖ.
4. Wörz R et al. Flupirtine in comparison with ehlomiezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (3536): 500–4.
5. Chou R, Qaseem A, Snow V et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Clinical Guidelines 2007.
6. Muller-Schwefe G, Uberall M. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW. Fortschr Med 2008; 149 (Suppl. 4): 153–61.
7. Bandura A, O’Leary A, Taylor СВ et al. Perceived self-efficacy and pain control: Opioid and nonopioid mechanisms. Personal and Social Psychology 1987; S3: 563–71.
8. Engel J. Flupirtine – a new central acting analgesic with unique chemical structure. Postgrad Med 1987; 63 (Suppl. 3): 15–7.
9. Hlavica P, Niebch G. Pharmacokinetics and biotransforma tion of the analgesic flupirtine in humans. Arzneimittelforschung 1985; 35 (1): 67–74.
10. Osborne NN, Cazevieille C, Wood J. Flupirtine, a Nonopioid Centrally Acting Analgesic, Acts as an NMDA Antagonist. Gen Pharmacol 1998; 30 (3): 255–63.
11. Michael A. Uberall et al. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1–18.
12. Болевые синдромы в неврологической практике. Под ред. чл.-кор. РАМН А.М.Вейна. М.: МЕДпресс-информ, 2001.
13. Кукушкин М.Л., Хитров Н.К. Общая патология боли.
М.: Медицина, 2004.
14. Darius H, Shror K. The action of Flupirtine on prostaglandine formation and platekets agregation in vitro. Arzneimittelforschung 1985; 35: 55–9.
15. Knost В, Flor H, Braun C, Birbaumer N. Cerebral processing of words and the development of chronic pain. Psychophysiology 1997; 34: 474–81.
16. Perovic S, Schleger C, Pergande G et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by NMDA and gpl20. Eur J Pharmacol Mol Pharmacol Sect 1994; 288: 27–33.
17. Schmidt C, Raspe H, Pfingsten M et al. Back pain in the German adult population. Spine 2007; 37 (18): 2005–11.
18. Bebenburg W von, Thiel K, Engel J, Sheldrick WS. Synthese und Molekulstruktur des konstitutionell neuartigen analgetikum Flupirtin. Chem Z 1981; 105: 77–81.
19. Szelenyi I, Nickel B, Borbe HO, Brune H. Mode of antinociceptive action on flupirtine in the rats. Br J Pharmacol 1989; 97: 835–42.
20. Von Korff M, Saunders K. The course of back pain in primary care. Spine. 1996; 21: 2833–7; discussion 2838–9 [PMID: 9112707].
21. Weiser T, Szelenyi I, Nickel B, Weinrich M. In vitro and in vivo findings about the muscle relaxing properties of flupirine. Naunyn-Schmiedeberg’s Arch Pharmacol 1992; 246 (Suppl. 1): R22.
22. Wörz R, Lobisch M, Schwittmann B et al. Effectiveness of flupirtine in chronic tension headache. Results of a double-blind study versus placebo. Fortschr Med 1995; 113 (32): 463–8.
Авторы
Ан.Б.Данилов, Н.С.Николаева
Кафедра нервных болезней факультета последипломного профессионального образования врачей
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Кафедра нервных болезней факультета последипломного профессионального образования врачей
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.